Loratadine: Difference between revisions
No edit summary |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Allergic rhinitis]]=== | ===[[Allergic rhinitis]]=== | ||
*10 mg | *10 mg PO once daily, OR | ||
*5 mg twice daily | *5 mg twice daily | ||
*Do not exceed 10 mg in 24 hours | *Do not exceed 10 mg in 24 hours | ||
===[[Urticaria]]=== | |||
*10 mg PO once daily | |||
**Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits. | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===[[Allergic rhinitis]]=== | ===[[Allergic rhinitis]]=== | ||
*Children aged | *Children aged ≥6 years old | ||
**10 mg PO once daily, OR | **10 mg PO once daily, OR | ||
*Children aged 2 to 5 | *Children aged 2 to 5 | ||
| Line 19: | Line 23: | ||
**Do not exceed 10 mg in 24 hours | **Do not exceed 10 mg in 24 hours | ||
**The ODT formulation is not recommended for younger children. | **The ODT formulation is not recommended for younger children. | ||
===[[Urticaria]]=== | |||
*Children aged ≥6 years old | |||
**10 mg PO once daily | |||
***Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits. | |||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *Should be safe for use during pregnancy; the risk of harm to the fetus is not expected based on limited human data; | ||
===Lactation risk=== | ===Lactation risk=== | ||
* | *Caution is advised; nursing mothers may use the medication for a short time. Both loratadine and its active metabolite pass readily into breast milk. There is no known risk of infant harm based on the drug's properties and the currently limited human data. | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
Latest revision as of 21:35, 20 May 2026
Administration
- Type: H1 antagonists (second generation)
- Dosage Forms: Tablets (chewable or orally disintegrating tablets [ODTs]), liquid-filled capsules, or a syrup (1 mg/mL solution)
- Routes of Administration: Oral
- Common Trade Names: Claritin
Adult Dosing
Allergic rhinitis
- 10 mg PO once daily, OR
- 5 mg twice daily
- Do not exceed 10 mg in 24 hours
Urticaria
- 10 mg PO once daily
- Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits.
Pediatric Dosing
Allergic rhinitis
- Children aged ≥6 years old
- 10 mg PO once daily, OR
- Children aged 2 to 5
- 5 mg PO once daily
- Do not exceed 10 mg in 24 hours
- The ODT formulation is not recommended for younger children.
Urticaria
- Children aged ≥6 years old
- 10 mg PO once daily
- Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits.
- 10 mg PO once daily
Special Populations
Pregnancy Rating
- Should be safe for use during pregnancy; the risk of harm to the fetus is not expected based on limited human data;
Lactation risk
- Caution is advised; nursing mothers may use the medication for a short time. Both loratadine and its active metabolite pass readily into breast milk. There is no known risk of infant harm based on the drug's properties and the currently limited human data.
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion: